Provided by Tiger Fintech (Singapore) Pte. Ltd.

SINO BIOPHARM

7.340
-0.030-0.41%
Volume:91.86M
Turnover:677.77M
Market Cap:137.71B
PE:35.04
High:7.480
Open:7.270
Low:7.240
Close:7.370
52wk High:9.120
52wk Low:2.634
Shares:18.76B
HK Float Shares:18.76B
Volume Ratio:1.09
T/O Rate:0.49%
Dividend:0.09
Dividend Rate:1.24%
EPS(LYR):0.209
ROE:15.40%
ROA:5.07%
PB:3.77
PE(LYR):35.04
PS:4.11

Loading ...

SINO BIOPHARM (01177): LM-302 "CLDN18.2 ADC" Included in Breakthrough Therapy Drug Program

Stock News
·
Aug 19

Sino Biopharmaceutical Ltd - Lm-302 Included in Breakthrough Therapeutic Designation Process by China's Nmpa

THOMSON REUTERS
·
Aug 19

Innovative Drug Stocks Experience Unexpected Decline: Where Is the Market Heading? SINO BIOPHARM Leads Drop by 7%, Hong Kong Stock Connect Innovative Drug ETF (520880) Falls Over 2%, High Premium Emerges Again

Deep News
·
Aug 19

Sino Biopharmaceutical's Earnings Outlook Brighter on Higher Margins -- Market Talk

Dow Jones
·
Aug 19

SINO BIOPHARM (01177) to Distribute Interim Dividend of HK$0.05 Per Share on September 23

Stock News
·
Aug 19

CICC Maintains Outperform Rating on SINO BIOPHARM (01177), Raises Target Price to HK$8.90

Stock News
·
Aug 19

Hong Kong Stock Market Announcements | LEAPMOTOR Achieves First Positive Semi-Annual Net Profit with H1 Net Profit of 33.03 Million Yuan

Stock News
·
Aug 18

Sino Biopharm's Profit Jumps in H1

MT Newswires Live
·
Aug 18

BRIEF-Sino Biopharmaceutical Declares Interim Dividend Of HK5 Cents Per Share

Reuters
·
Aug 18

Sino Biopharmaceutical Stock Rises 1.2% in Hong Kong, Outperforms Competitors

Dow Jones
·
Aug 18

Sino Biopharmaceutical - Interim Dividend of HK5 Cents per Share

THOMSON REUTERS
·
Aug 18

Sino Biopharmaceutical - Hy Profit Attributable RMB 3.09 Bln

THOMSON REUTERS
·
Aug 18

Sino Biopharmaceutical - Hy Revenue RMB 17.57 Bln

THOMSON REUTERS
·
Aug 18

Sino Biopharmaceutical Stock Advances 2.6% in Hong Kong

Dow Jones
·
Aug 15

Sino Biopharmaceutical - China's Nmpa Accepts Clinical Trial Application for Tqb3142 "Bcl-Xl Protac"

THOMSON REUTERS
·
Aug 12

Sino Biopharmaceutical's Investigational New Drug Application for Tumor Medicine Accepted by Chinese Regulators

MT Newswires Live
·
Aug 12

BRIEF-Sino Biopharmaceutical Says Application For Clinical Trial Of TQB3122 Accepted By NMPA

Reuters
·
Aug 11

Sino Biopharmaceutical - Application for Clinical Trial of Tqb3122 "Parp1 Inhibitor" Accepted by Nmpa

THOMSON REUTERS
·
Aug 11

Sino Biopharmaceutical Stock Rises 1.0% in Hong Kong

Dow Jones
·
Aug 11

Sino Biopharmaceutical Receives Chinese Regulatory Nod for Mid-stage Study of Tumor Drug

MT Newswires Live
·
Aug 08